
    
      Asymptomatic, endomysial-antibody positive adults will be randomized to either continue with
      a normal, gluten-containing diet or start an intervention with a gluten-free diet
      irrespective of the small-bowel mucosal morphology. Several celiac-disease associated
      histological, serological and clinical markers will be evaluated both at baseline and after
      one year on trial.
    
  